Cancer Treatment Reviews
Volume 29, Issue 3 , Pages 227-229 , June 2003

Adding androgen suppression to radiotherapy may improve disease-free survival over radiotherapy alone in locally advanced prostate cancer: Abstracted from: Bolla M, Collette L, Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103–6.

References 

  1. Bolla M, Gonzalez D, Warde P, et al.  Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N. Engl. J. Med. 1997;337:295–300
  2. Pilepich MV, Krall JM, al-Sarraf M, et al.  Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology. 1995;45:616–623
  3. Pilepich MV, Winter K, John MJ, et al.  Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 2001;50:1243–1252
  4. Hatano T, Igarashi H, Nakada J, et al.  Bone fracture receiving LH-RH agonists for prostatic cancer. Nippon Hinyokika Gakkai Zasshi – Jpn. J. Urol. 2000;91:542–546
  5. Smith MR, McGovern FJ, Zietman AL, et al.  Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. [comment] N. Engl. J. Med. 2001;345:948–955
  6. Berruti A, Dogliotti L, Terrone C, et al.  Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J. Urol. 2002;167:2361–2367
  7. Hanks GE, Lu J, Machtay M, et al.  RTOG Protocol 9202: a phase III trial of the use of long term androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. Proc. ASCO. 2000;19:327a
  8. Zelefsky MJ, Leibel SA, Burman CM, et al.  Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 1994;29:755–761
  9. Roach M, Lu J, Lawton C, et al.  A phase III trial comparing whole-pelvic (WP) to prostate only (PO) radiotherapy and neoadjuvant to adjuvant total androgen suppression (TAS): preliminary analysis of RTOG 9413. Int. J. Radiat. Oncol. Biol. Phys. 2001;51:3
  10. Coen JJ, Zietman AL, Thakral H, et al.  Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. J. Clin. Oncol. 2002;20:3199–3205

☆ Sources of funding: Not specified. Astra Zenica provided goserelin.

☆☆ Correspondence: M. Bolla, Radiotherapy Department, University Hospital, Grenoble, France. E-mail: MBolla@chu-grenoble.fr.

★ Abstract provided by Bazian Ltd., London.

PII: S0305-7372(03)00099-9

doi: 10.1016/S0305-7372(03)00099-9

Cancer Treatment Reviews
Volume 29, Issue 3 , Pages 227-229 , June 2003

Article Tools